Public offering nets $211.5mm for uniQure

15:40 EDT 11 Sep 2019 | Elsevier Business Intelligence

UniQure NV (gene therapies for hemophilia, Huntington’s disease, and other severe genetic diseases) netted $211.5mm through...

Original Article: Public offering nets $211.5mm for uniQure


More From BioPortfolio on "Public offering nets $211.5mm for uniQure"

Quick Search

Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Huntington's Disease
Huntington's disease is a hereditary disease caused by a defect in a single gene on Chromosome 4 that is inherited in an autosomal dominant fashion. The defect causes a part of DNA, called a CAG repeat, to occur many more times than it is supposed to...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...